JP2009503118A - 異常な細胞膜生理学およびウイルス膜生理学における活性な生物学的物質の使用 - Google Patents
異常な細胞膜生理学およびウイルス膜生理学における活性な生物学的物質の使用 Download PDFInfo
- Publication number
- JP2009503118A JP2009503118A JP2008527335A JP2008527335A JP2009503118A JP 2009503118 A JP2009503118 A JP 2009503118A JP 2008527335 A JP2008527335 A JP 2008527335A JP 2008527335 A JP2008527335 A JP 2008527335A JP 2009503118 A JP2009503118 A JP 2009503118A
- Authority
- JP
- Japan
- Prior art keywords
- active
- histone
- cells
- active biological
- cell membrane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Physiology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
フラビウイルス科
トガウイルス科
コロナウイルス科
アルテリウイルス科
ラブドウイルス科
パラミクソウイルス科
フィロウイルス科
ボルナウイルス科
オルトミクソウイルス科
ブニヤウイルス科
アレナウイルス科
レトロウイルス科
ヘパドナウイルス科
ヘルペスウイルス科
ポックスウイルス科
アスファウイルス科
・その血管を介した固形腫瘍への供給を停止させること、
・ウイルスに感染した細胞を全て殺すこと
のための作用因としての、
・ヒストン、
・共有結合により修飾されたヒストン、
・ヒストン様ポリペプチド、
・ヒストンおよびヒストン様ポリペプチドの生物的活性配列
を含む物質群から選択される少なくとも1つの成分を含有するか、または、そのような少なくとも1つの成分からなる活性な生物学的物質によって達成される。
H1+nPS −> H1α[PS]n
mH1α[PS]n −> {H1α[PS]n}m
Claims (4)
- ヒトおよび哺乳動物生物における異常な細胞膜生理学およびウイルス膜生理学における活性な生物学的物質の使用であって、前記活性物質が診断および/または治療での特性を有し、かつ、
・固形腫瘍への供給をその血管の内皮細胞のアポトーシスおよび膜損傷によって停止させること、
・ウイルスが感染した細胞をアポトーシスおよび膜損傷によって全て殺すこと、
・乱れた脂質非対称性を有する腫瘍細胞を全て殺すこと
のための作用因としての、
・ヒストン、
・共有結合により修飾されたポリペプチド、
・ヒストンおよびヒストン様ポリペプチドの生物的活性配列
を含む物質群から選択される少なくとも1つの成分を含有するか、または、そのような少なくとも1つの成分からなる活性な生物学的物質の、使用。 - 固形腫瘍内の血管形成、または、固形腫瘍と接触している血管形成を阻害または抑制するための作用因としての、請求項1に記載される活性な生物学的物質。
- 診断目的のためのマーカー分子(例えば、蛍光基)と併用される、請求項1に記載される活性な生物学的物質。
- 相乗効果を最大限にするために、活性物質の細胞増殖抑制性および/またはウイルス抑制性による混合治療のための細胞増殖抑制剤および/またはウイルス抑制剤と併用される、請求項1に記載される活性な生物学的物質。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102005037602 | 2005-08-05 | ||
PCT/EP2006/007764 WO2007017212A2 (de) | 2005-08-05 | 2006-08-04 | Verwendung eines biologischen wirkstoffes bei abnormalen zellulären und viralen membranphysiologien |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012230532A Division JP2013067620A (ja) | 2005-08-05 | 2012-10-18 | 異常な細胞膜生理学およびウイルス膜生理学における活性な生物学的物質の使用 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2009503118A true JP2009503118A (ja) | 2009-01-29 |
Family
ID=37528468
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008527335A Pending JP2009503118A (ja) | 2005-08-05 | 2006-08-04 | 異常な細胞膜生理学およびウイルス膜生理学における活性な生物学的物質の使用 |
JP2012230532A Ceased JP2013067620A (ja) | 2005-08-05 | 2012-10-18 | 異常な細胞膜生理学およびウイルス膜生理学における活性な生物学的物質の使用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012230532A Ceased JP2013067620A (ja) | 2005-08-05 | 2012-10-18 | 異常な細胞膜生理学およびウイルス膜生理学における活性な生物学的物質の使用 |
Country Status (4)
Country | Link |
---|---|
US (2) | US8778875B2 (ja) |
EP (1) | EP1912678A2 (ja) |
JP (2) | JP2009503118A (ja) |
WO (1) | WO2007017212A2 (ja) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003530360A (ja) * | 2000-04-12 | 2003-10-14 | インプリクス リミテッド | 薬剤送達のためのペプチド複合体 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4818763A (en) * | 1984-01-12 | 1989-04-04 | Volker Rusch | Biologically active substance with hormonal properties, production process thereof and utilization of histones for medical purposes |
DE4000154A1 (de) * | 1990-01-04 | 1991-07-11 | Symbiotec Gmbh | Chemotherapeutisches mittel, insbesondere zur behandlung von krebserkrankungen |
US5780432A (en) * | 1990-12-28 | 1998-07-14 | Allegheny University Of The Health Sciences | Therapeutic method for treatment of carcinoma or autoimmune diseases |
GB9209874D0 (en) * | 1992-05-07 | 1992-06-24 | Ml Lab Plc | Pharmaceutical compositions |
US5753789A (en) * | 1996-07-26 | 1998-05-19 | Yale University | Oligonucleotides containing L-nucleosides |
US20030017987A1 (en) * | 1997-04-11 | 2003-01-23 | Michael Zeppezauer | Therapeutic, prophylactic, and diagnostic agent for cancer, useful for characterizing cancer cells with individual properties |
US6884423B1 (en) * | 1998-08-13 | 2005-04-26 | Symbiotec Gmbh | Antimicrobial histone H1 compositions, kits, and methods of use thereof |
US6565854B2 (en) * | 1998-08-13 | 2003-05-20 | Philadelphia Health And Education Corporation | Antimicrobial histone H1 compositions, kits, and methods of use thereof |
DE10001113A1 (de) * | 2000-01-13 | 2001-07-26 | Strathmann Ag & Co | Rekombinante Herstellung von humanen Histon 1-Subtypen sowie deren Verwendung für therapeutische Zwecke |
US20030125239A1 (en) * | 2001-02-02 | 2003-07-03 | Andrea Crisanti | Compositions for drug delivery |
US20040219140A1 (en) * | 2001-02-22 | 2004-11-04 | Reiner Class | Compositions and methods for preventing platelet aggregation |
WO2003086273A2 (en) * | 2002-04-08 | 2003-10-23 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Histone conjugates and uses thereof |
US7056683B2 (en) * | 2002-11-12 | 2006-06-06 | Massachusetts Institute Of Technology | Genetically encoded fluorescent reporters of kinase, methyltransferase, and acetyl-transferase activities |
US20070110768A1 (en) * | 2005-03-29 | 2007-05-17 | Reiner Class | Use of histones for the early diagnosis and/or preventive therapy of virally-infected living cells and a biochip for carrying out said diagnosis |
-
2006
- 2006-08-04 WO PCT/EP2006/007764 patent/WO2007017212A2/de active Application Filing
- 2006-08-04 US US11/989,784 patent/US8778875B2/en not_active Expired - Fee Related
- 2006-08-04 EP EP06776633A patent/EP1912678A2/de active Pending
- 2006-08-04 JP JP2008527335A patent/JP2009503118A/ja active Pending
-
2012
- 2012-10-18 JP JP2012230532A patent/JP2013067620A/ja not_active Ceased
-
2014
- 2014-06-10 US US14/300,591 patent/US20140315813A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003530360A (ja) * | 2000-04-12 | 2003-10-14 | インプリクス リミテッド | 薬剤送達のためのペプチド複合体 |
JP2004528266A (ja) * | 2000-04-12 | 2004-09-16 | インプリクス リミテッド | 薬物送達用組成物 |
Also Published As
Publication number | Publication date |
---|---|
WO2007017212A3 (de) | 2007-06-14 |
JP2013067620A (ja) | 2013-04-18 |
EP1912678A2 (de) | 2008-04-23 |
US20140315813A1 (en) | 2014-10-23 |
US8778875B2 (en) | 2014-07-15 |
WO2007017212A2 (de) | 2007-02-15 |
US20090304597A1 (en) | 2009-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yang et al. | Targeting cell death: pyroptosis, ferroptosis, apoptosis and necroptosis in osteoarthritis | |
Borgas et al. | Cigarette smoke disrupted lung endothelial barrier integrity and increased susceptibility to acute lung injury via histone deacetylase 6 | |
Jia et al. | Targeting macrophage TFEB-14-3-3 epsilon Interface by naringenin inhibits abdominal aortic aneurysm | |
CN107412260B (zh) | cGAS-STING通路激活剂及其用途 | |
Zhang et al. | MicroRNA-325-3p protects the heart after myocardial infarction by inhibiting RIPK3 and programmed necrosis in mice | |
US8415293B2 (en) | Peptide mediators of cholesterol efflux | |
WO2016145234A2 (en) | Use of mk2 inhibitor peptide-containing compositions for treating non-small cell lung cancer with same | |
US20060241066A1 (en) | Decoy composition for treating and preventing inflammatory disease | |
CZ293399A3 (cs) | Kombinovaná terapie tumor-supresorovým gelem a chemoterapie při léčbě nádorových onemocnění | |
Uzair et al. | Potential uses of venom proteins in treatment of HIV | |
JP2023022242A (ja) | がんを処置するための方法および組成物 | |
Thierry et al. | NETs by-products and extracellular DNA may play a key role in COVID-19 pathogenesis: incidence on patient monitoring and therapy | |
Xu et al. | Molecular mechanism and therapy application of necrosis during myocardial injury | |
EP2121746A2 (en) | Potent and selective mediators of cholesterol efflux | |
Zhang et al. | Pyroptosis in inflammatory bone diseases: Molecular insights and targeting strategies | |
Dong et al. | Blocking the cytohesin-2/ARF1 axis by SecinH3 ameliorates osteoclast-induced bone loss via attenuating JNK-mediated IRE1 endoribonuclease activity | |
Lezhnin et al. | Oncotoxic proteins in cancer therapy: Mechanisms of action | |
JP2009503118A (ja) | 異常な細胞膜生理学およびウイルス膜生理学における活性な生物学的物質の使用 | |
US20080293652A1 (en) | Combination of Ad-P53 and Chemotherapy for the Treatment of Tumours | |
Nold et al. | Activated protein C downregulates p38 mitogen-activated protein kinase and improves clinical parameters in an in-vivo model of septic shock | |
KR20100106952A (ko) | 급성 인간 골수성 백혈병 세포를 죽이는 트롬보포이에틴 수용체 효능제 (tpora) | |
Williams et al. | Targeting multiple angiogenic pathways for the treatment of neuroblastoma | |
Goddard et al. | Mechanisms of Immune Sensing of DNA Damage | |
Silberstein | Is PNC-27 and PNC-28 the Best way to cure Cancer? | |
Todosenko et al. | Prohibitions in the meta-inflammatory response: a review |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090424 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111108 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120206 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120213 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120307 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120619 |